Tripterygium wilfordii Hook. f. and Xinfeng Capsule in Rheumatoid Arthritis: A Review of Clinical Evidence, Molecular Mechanisms, and Translational Perspectives - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Mechanisms of Tripterygium wilfordii Hook. f. and Xinfeng Capsule in the Management of Rheumatoid Arthritis: A Comprehensive Review of Clinical Evidence and Translational Insights

  • By

  • Wen, Jianting

  • Liu, Jian

  • June 8, 2026

Share

Objective:

To summarize the efficacy, mechanisms, clinical evidence, and translational challenges of TWHf-derived monomers, Tripterygium Glycosides Tablets (TGT), and Xinfeng Capsule (XFC) in rheumatoid arthritis (RA).

Approach:
    Key Findings:
    • Preclinical evidence indicates that TWHf-derived compounds regulate multiple RA-related processes, including NF-κB and PI3K/AKT/mTOR signaling pathways, ROS-NLRP3 inflammasome activation, synovial hyperplasia, angiogenesis, and immune cell dysfunction.
    • XFC exhibits broader multi-component and multi-target regulation compared to isolated monomers, involving epigenetic modulation, NETosis, cuproptosis, pyroptosis, oxidative stress, and coagulation homeostasis.
    • Clinical studies suggest that TWHf-related preparations may improve disease activity, joint symptoms, and inflammatory markers, whether used alone or in combination with conventional DMARDs or biologics.
    Interpretation:

    While TWHf and XFC show promise in managing RA, challenges such as toxicity, insufficient high-quality multicenter RCTs, limited standardization, and a lack of personalized dosing remain.

    Limitations:
    • Toxicity concerns associated with TWHf.
    • Insufficient high-quality multicenter randomized controlled trials (RCTs).
    • Limited standardization of formulations.
    • Lack of personalized dosing strategies.
    Conclusion:

    Future studies should focus on standardized formulations, rigorous clinical evaluation, safety monitoring, and toxicity-attenuating delivery systems, as well as biomarker-guided precision application of TWHf and XFC in RA.

Original Source(s)

Related Content